The Bear Case For Bionano Genomics Carries More Weight_老虎社区_美港股上老虎

The Bear Case For Bionano Genomics Carries More Weight

InvestorPlace2021-06-07

BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

105

Meshaarias72
·2021-06-07
Like n comment pls
回复
点赞
举报
Sysy
·2021-06-07
Huat
回复
1
举报
收起
- Meshaarias72:
  Yes
  2021-06-07
  回复
  举报
Bll
·2021-06-07
Good news
回复
3
举报
收起
- Meshaarias72:
  Yes
  2021-06-07
  回复
  举报
PREM
·2021-06-07
Any guess Short term target?
回复
点赞
举报
b1gman
·2021-06-07
pls help!:D
回复
3
举报
KW1
·2021-06-07
Great. Buy bngo
回复
3
举报
76b16b78
·2021-06-07
Please Help to Like & Comment to me
回复
2
举报
收起
- b1gman:
  help too
  2021-06-07
  回复
  举报
Kendaman
·2021-06-07
Huat ah
回复
3
举报
Vivienrose
·2021-06-07
Hi please me reply thank u
回复
3
举报
收起
- SCP03:
  there u go!
  2021-06-07
  回复
  举报
- SCP03:
  replied...dunno why the translation
  2021-06-07
  回复
  举报
Juelo
·2021-06-07
yay
回复
4
举报
Phoenix5104
·2021-06-07
Holding on and going strong!Please like and comment too!
回复
3
举报
收起
- ALi_BaBa:
  Great
  2021-06-07
  回复
  举报
zhangming
·2021-06-07
AMC TO THE MOON!
回复
5
举报
iamateh
·2021-06-07
like and comment pls!!
回复
5
举报
收起
- EmChung:
  Nice
  2021-06-07
  回复
  举报
- zhangming:
  AMC TO THE MOON!
  2021-06-07
  回复
  举报
a085d41
·2021-06-07
Like and share
回复
6
举报
HappyTrade
·2021-06-07
Looking forward to double digit soon..... [财迷]
回复
3
举报
HappyTrade
·2021-06-07
Waiting for double digit again....hopefully soon[财迷]
回复
4
举报
Sucrammis
·2021-06-07
[Cool]
回复
5
举报
WayneSing
·2021-06-07
comment and like thanks
回复
3
举报
收起
- Hodl:
  Commented
  2021-06-07
  回复
  举报
- Pettan:
  Pls like and comment too 😍
  2021-06-07
  回复
  举报
- Etet1985:
  ok
  2021-06-07
  回复
  举报
查看更多 2 条评论
dar
·2021-06-07
Wow
回复
4
举报
收起
- WayneSing:
  return my comment and like thanks
  2021-06-07
  回复
  举报
- Wellyanto:
  Done
  2021-06-07
  回复
  举报
MagPie
·2021-06-07
Time to observe whether it will break through the resistance
回复
2
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1112319097?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-06-07 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112319097","market":"us","top_or_hot":-1,"title":"The Bear Case For Bionano Genomics Carries More Weight","media":"InvestorPlace","content":"<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">网页链接</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNGO","symbol_name":"Bionano Genomics","start_time":0,"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","article_id":"1112319097","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","pubTimestamp":1623055213,"columns":[],"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNGO":"Bionano Genomics"},"translate_title":"Bionano基因组学的熊案例更有分量","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNGO":0.9},"content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":114697201,"gmtCreate":1623071209103,"gmtModify":1634037301458,"author":{"id":"3577781617271173","authorId":"3577781617271173","name":"Meshaarias72","avatar":"https://static.tigerbbs.com/c5282cda6a9d3948fc067b21adcb578c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577781617271173","authorIdStr":"3577781617271173"},"htmlText":"Like n comment pls","listText":"Like n comment pls","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114697201","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114845765,"gmtCreate":1623069246857,"gmtModify":1634037325401,"author":{"id":"3581726174893746","authorId":"3581726174893746","name":"Sysy","avatar":"https://static.tigerbbs.com/f89400ba2f20ed80423858c0f6a3d8ee","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581726174893746","authorIdStr":"3581726174893746"},"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/114845765","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4617520,"gmtCreate":1623071228998,"gmtModify":1635333553444,"authorId":3577781617271173,"author":{"id":3577781617271173,"idStr":"3577781617271173","authorId":3577781617271173,"name":"Meshaarias72","avatar":"https://static.tigerbbs.com/c5282cda6a9d3948fc067b21adcb578c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114845765,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"EN"},{"id":114895628,"gmtCreate":1623063693264,"gmtModify":1634037372429,"author":{"id":"3575152525326279","authorId":"3575152525326279","name":"Bll","avatar":"https://static.tigerbbs.com/b372fc92d67296f5ba36af78d1d6e935","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575152525326279","authorIdStr":"3575152525326279"},"htmlText":"Good news&nbsp;","listText":"Good news&nbsp;","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/114895628","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4617525,"gmtCreate":1623071235879,"gmtModify":1635333552817,"authorId":3577781617271173,"author":{"id":3577781617271173,"idStr":"3577781617271173","authorId":3577781617271173,"name":"Meshaarias72","avatar":"https://static.tigerbbs.com/c5282cda6a9d3948fc067b21adcb578c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114895628,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"EN"},{"id":114807193,"gmtCreate":1623062962912,"gmtModify":1634037378171,"author":{"id":"3583719080393906","authorId":"3583719080393906","name":"PREM","avatar":"https://static.tigerbbs.com/bd4e9099a744c8af75ebaa2e0ce2f09b","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3583719080393906","authorIdStr":"3583719080393906"},"htmlText":"Any guess Short term target?&nbsp;","listText":"Any guess Short term target?&nbsp;","text":"Any guess Short term target?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114807193","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114171287,"gmtCreate":1623061205449,"gmtModify":1634037386788,"author":{"id":"3583748261189325","authorId":"3583748261189325","name":"b1gman","avatar":"https://static.tigerbbs.com/6a1489bd78edf55795eddbec4fca6280","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3583748261189325","authorIdStr":"3583748261189325"},"htmlText":"pls help!:D","listText":"pls help!:D","text":"pls help!:D","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114171287","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114147916,"gmtCreate":1623060859135,"gmtModify":1634037389709,"author":{"id":"3563714281601583","authorId":"3563714281601583","name":"KW1","avatar":"https://static.tigerbbs.com/094e3f8fd8b3de3da976515926ed1403","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3563714281601583","authorIdStr":"3563714281601583"},"htmlText":"Great. Buy bngo","listText":"Great. Buy bngo","text":"Great. Buy bngo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114147916","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114147011,"gmtCreate":1623060852633,"gmtModify":1634037389830,"author":{"id":"3585283371231222","authorId":"3585283371231222","name":"76b16b78","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3585283371231222","authorIdStr":"3585283371231222"},"htmlText":"Please Help to Like &amp; Comment to me","listText":"Please Help to Like &amp; Comment to me","text":"Please Help to Like & Comment to me","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/114147011","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4615940,"gmtCreate":1623062674062,"gmtModify":1635333685168,"authorId":3583748261189325,"author":{"id":3583748261189325,"idStr":"3583748261189325","authorId":3583748261189325,"name":"b1gman","avatar":"https://static.tigerbbs.com/6a1489bd78edf55795eddbec4fca6280","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114147011,"type":1,"supId":0,"prevId":0,"content":"help too","text":"help too","html":"help too"}],"langContent":"EN"},{"id":114156935,"gmtCreate":1623059545927,"gmtModify":1634037397206,"author":{"id":"3578003575720363","authorId":"3578003575720363","name":"Kendaman","avatar":"https://static.tigerbbs.com/ede8fd0a4f53700b144284ba889b0719","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3578003575720363","authorIdStr":"3578003575720363"},"htmlText":"Huat ah","listText":"Huat ah","text":"Huat ah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114156935","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114159207,"gmtCreate":1623059385309,"gmtModify":1634037399474,"author":{"id":"3575585519231161","authorId":"3575585519231161","name":"Vivienrose","avatar":"https://static.tigerbbs.com/def4c9c09d2d61a66e1bd9447e42aa29","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575585519231161","authorIdStr":"3575585519231161"},"htmlText":"Hi please me reply thank u","listText":"Hi please me reply thank u","text":"Hi please me reply thank u","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/114159207","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4615718,"gmtCreate":1623061078645,"gmtModify":1635333701141,"authorId":3561986763872297,"author":{"id":3561986763872297,"idStr":"3561986763872297","authorId":3561986763872297,"name":"SCP03","avatar":"https://static.tigerbbs.com/2abf42c22b2629cf57b473d657ee801e","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114159207,"type":1,"supId":0,"prevId":0,"content":"there u go!","text":"there u go!","html":"there u go!"},{"id":4615720,"gmtCreate":1623061101679,"gmtModify":1635333700897,"authorId":3561986763872297,"author":{"id":3561986763872297,"idStr":"3561986763872297","authorId":3561986763872297,"name":"SCP03","avatar":"https://static.tigerbbs.com/2abf42c22b2629cf57b473d657ee801e","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114159207,"type":1,"supId":4615718,"prevId":0,"content":"replied...dunno why the translation","text":"replied...dunno why the translation","html":"replied...dunno why the translation"}],"langContent":"EN"},{"id":114168499,"gmtCreate":1623058121111,"gmtModify":1631890695755,"author":{"id":"3584151097809421","authorId":"3584151097809421","name":"Juelo","avatar":"https://static.tigerbbs.com/44b1b2a7ad3407d486dd49dd047d2b80","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3584151097809421","authorIdStr":"3584151097809421"},"htmlText":"yay","listText":"yay","text":"yay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114168499","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114169621,"gmtCreate":1623057858763,"gmtModify":1634037410675,"author":{"id":"3585694968236372","authorId":"3585694968236372","name":"Phoenix5104","avatar":"https://static.tigerbbs.com/f0a316ae2880cadff61373ca7d5cf06a","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3585694968236372","authorIdStr":"3585694968236372"},"htmlText":"Holding on and going strong!Please like and comment too!","listText":"Holding on and going strong!Please like and comment too!","text":"Holding on and going strong!Please like and comment too!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/114169621","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4615287,"gmtCreate":1623058109533,"gmtModify":1635333731612,"authorId":3564105303063302,"author":{"id":3564105303063302,"idStr":"3564105303063302","authorId":3564105303063302,"name":"ALi_BaBa","avatar":"https://static.tigerbbs.com/d89722c800111c9c885624fce940701f","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114169621,"type":1,"supId":0,"prevId":0,"content":"Great","text":"Great","html":"Great"}],"langContent":"EN"},{"id":114187954,"gmtCreate":1623057717278,"gmtModify":1634037411645,"author":{"id":"3582333701245743","authorId":"3582333701245743","name":"zhangming","avatar":"https://static.tigerbbs.com/b068e93dada633a2bbb6c31bd21743c2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582333701245743","authorIdStr":"3582333701245743"},"htmlText":"AMC TO THE MOON!","listText":"AMC TO THE MOON!","text":"AMC TO THE MOON!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114187954","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114189486,"gmtCreate":1623057210645,"gmtModify":1634037417090,"author":{"id":"3554804006357295","authorId":"3554804006357295","name":"iamateh","avatar":"https://static.tigerbbs.com/cfa6492594e288f70d24f72146aeec45","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3554804006357295","authorIdStr":"3554804006357295"},"htmlText":"like and comment pls!!&nbsp;","listText":"like and comment pls!!&nbsp;","text":"like and comment pls!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/114189486","repostId":1112319097,"repostType":2,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4615319,"gmtCreate":1623058332964,"gmtModify":1631894745692,"authorId":3566723689439669,"author":{"id":3566723689439669,"idStr":"3566723689439669","authorId":3566723689439669,"name":"EmChung","avatar":"https://static.tigerbbs.com/99db9b9b2d5d303db43970c31a6ba528","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114189486,"type":1,"supId":0,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"},{"id":4615206,"gmtCreate":1623057727493,"gmtModify":1631894745683,"authorId":3582333701245743,"author":{"id":3582333701245743,"idStr":"3582333701245743","authorId":3582333701245743,"name":"zhangming","avatar":"https://static.tigerbbs.com/b068e93dada633a2bbb6c31bd21743c2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114189486,"type":1,"supId":0,"prevId":0,"content":"AMC TO THE MOON!","text":"AMC TO THE MOON!","html":"AMC TO THE MOON!"}],"langContent":"EN"},{"id":114111119,"gmtCreate":1623056676431,"gmtModify":1631890474277,"author":{"id":"3581902399516412","authorId":"3581902399516412","name":"a085d41","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581902399516412","authorIdStr":"3581902399516412"},"htmlText":"Like and share&nbsp;","listText":"Like and share&nbsp;","text":"Like and share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114111119","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114110443,"gmtCreate":1623056503282,"gmtModify":1634095790653,"author":{"id":"3561676944889444","authorId":"3561676944889444","name":"HappyTrade","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3561676944889444","authorIdStr":"3561676944889444"},"htmlText":"Looking forward to double digit soon.....&nbsp;[财迷]&nbsp;","listText":"Looking forward to double digit soon.....&nbsp;[财迷]&nbsp;","text":"Looking forward to double digit soon..... [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114110443","repostId":1112319097,"repostType":2,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":114137632,"gmtCreate":1623056443626,"gmtModify":1634095791113,"author":{"id":"3561676944889444","authorId":"3561676944889444","name":"HappyTrade","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3561676944889444","authorIdStr":"3561676944889444"},"htmlText":"Waiting for double digit again....hopefully soon[财迷]&nbsp;","listText":"Waiting for double digit again....hopefully soon[财迷]&nbsp;","text":"Waiting for double digit again....hopefully soon[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114137632","repostId":1112319097,"repostType":2,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":114135453,"gmtCreate":1623056360672,"gmtModify":1634095792017,"author":{"id":"3567510698843882","authorId":"3567510698843882","name":"Sucrammis","avatar":"https://static.tigerbbs.com/b53e2d1cd4fdf176174f088adbd03e1c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3567510698843882","authorIdStr":"3567510698843882"},"htmlText":"[Cool]&nbsp;","listText":"[Cool]&nbsp;","text":"[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114135453","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":114197120,"gmtCreate":1623055953860,"gmtModify":1634095797236,"author":{"id":"3584427442291849","authorId":"3584427442291849","name":"WayneSing","avatar":"https://static.tigerbbs.com/9ba5be2ddf8347d41eed59a863adfe57","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3584427442291849","authorIdStr":"3584427442291849"},"htmlText":"comment and like thanks","listText":"comment and like thanks","text":"comment and like thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/114197120","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4614803,"gmtCreate":1623056022296,"gmtModify":1635333773557,"authorId":3579666066637422,"author":{"id":3579666066637422,"idStr":"3579666066637422","authorId":3579666066637422,"name":"Hodl","avatar":"https://static.tigerbbs.com/d591a82f579d3114da9795812a4217a0","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114197120,"type":1,"supId":0,"prevId":0,"content":"Commented","text":"Commented","html":"Commented"},{"id":4614806,"gmtCreate":1623056036626,"gmtModify":1635333773305,"authorId":3576213741857476,"author":{"id":3576213741857476,"idStr":"3576213741857476","authorId":3576213741857476,"name":"Pettan","avatar":"https://static.tigerbbs.com/eea8055165cc8ba5c3e2968ccdcd6400","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114197120,"type":1,"supId":0,"prevId":0,"content":"Pls like and comment too 😍","text":"Pls like and comment too 😍","html":"Pls like and comment too 😍"},{"id":4614897,"gmtCreate":1623056481117,"gmtModify":1635333766350,"authorId":3584157211271817,"author":{"id":3584157211271817,"idStr":"3584157211271817","authorId":3584157211271817,"name":"Etet1985","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114197120,"type":1,"supId":4614806,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":4614969,"gmtCreate":1623056784335,"gmtModify":1635333759781,"authorId":3570360623104656,"author":{"id":3570360623104656,"idStr":"3570360623104656","authorId":3570360623104656,"name":"zhen130","avatar":"https://static.tigerbbs.com/553509e2e649eaf0d39f267a7e6de1a1","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114197120,"type":1,"supId":4614806,"prevId":0,"content":"Pls reply <u>too</u>","text":"Pls reply <u>too</u>","html":"Pls reply <u>too</u>"},{"id":4615791,"gmtCreate":1623061649899,"gmtModify":1635333695503,"authorId":3576213741857476,"author":{"id":3576213741857476,"idStr":"3576213741857476","authorId":3576213741857476,"name":"Pettan","avatar":"https://static.tigerbbs.com/eea8055165cc8ba5c3e2968ccdcd6400","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114197120,"type":1,"supId":4614806,"prevId":0,"content":"Nice, thanks 😍","text":"Nice, thanks 😍","html":"Nice, thanks 😍"}],"langContent":"EN"},{"id":114194339,"gmtCreate":1623055871421,"gmtModify":1634095798174,"author":{"id":"3554840164932540","authorId":"3554840164932540","name":"dar","avatar":"https://static.tigerbbs.com/e4bcf35c6c1a9221c5cc6cce74413dff","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3554840164932540","authorIdStr":"3554840164932540"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/114194339","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4614787,"gmtCreate":1623055976507,"gmtModify":1635333774853,"authorId":3584427442291849,"author":{"id":3584427442291849,"idStr":"3584427442291849","authorId":3584427442291849,"name":"WayneSing","avatar":"https://static.tigerbbs.com/9ba5be2ddf8347d41eed59a863adfe57","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114194339,"type":1,"supId":0,"prevId":0,"content":"return my comment and like thanks","text":"return my comment and like thanks","html":"return my comment and like thanks"},{"id":4617116,"gmtCreate":1623069371097,"gmtModify":1635333587574,"authorId":3578723450181101,"author":{"id":3578723450181101,"idStr":"3578723450181101","authorId":3578723450181101,"name":"Wellyanto","avatar":"https://static.tigerbbs.com/da46836141f0e6c7ed8114362646057a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":114194339,"type":1,"supId":4614787,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"},{"id":114195858,"gmtCreate":1623055814374,"gmtModify":1631885485304,"author":{"id":"3573728905231423","authorId":"3573728905231423","name":"MagPie","avatar":"https://static.tigerbbs.com/86bf766e96cabebb79ece6877432d5da","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573728905231423","authorIdStr":"3573728905231423"},"htmlText":"Time to observe whether it will break through the resistance","listText":"Time to observe whether it will break through the resistance","text":"Time to observe whether it will break through the resistance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114195858","repostId":1112319097,"repostType":4,"repost":{"id":"1112319097","kind":"news","pubTimestamp":1623055213,"share":"https://www.laohu8.com/m/news/1112319097?lang=&edition=full","pubTime":"2021-06-07 16:40","market":"us","language":"en","title":"The Bear Case For Bionano Genomics Carries More Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=1112319097","media":"InvestorPlace","summary":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomic","content":"<blockquote><b>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.</b></blockquote><p>Bionano Genomics&nbsp;rose&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;Monday.</p><p><img src=\"https://static.tigerbbs.com/c142fe03bfec78aa892afb92fb36fd80\" tg-width=\"662\" tg-height=\"439\"></p><p>It’s been quite the year for the life sciences company,<b>Bionano Genomics</b>(NASDAQ:<b><u>BNGO</u></b>). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.</p><p><img src=\"https://static.tigerbbs.com/a8dcd0cd230a30d7e81413d8aad0e588\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Connect world / Shutterstock.com</p><p>Reddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.</p><p>Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.</p><p>With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.</p><p><b>The Bull Case</b></p><p>Naturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rival<b>Pacific Biosciences</b>(NASDAQ:<b><u>PACB</u></b>). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.</p><p>The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.</p><p>Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.</p><p><b>The Bear Case</b></p><p>There are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.</p><p>Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.</p><p>Furthermore,&nbsp; it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.</p><p><b>Concluding Thoughts On BNGO Stock</b></p><p>Six-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.</p><p>Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.</p><p><i>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Case For Bionano Genomics Carries More Weight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Case For Bionano Genomics Carries More Weight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences ...</p>\n\n<a href=\"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/05/the-bear-case-for-bngo-stock-carries-more-weight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112319097","content_text":"BNGO is up against some stiff competition as it seeks to hold on to its recent gains.Bionano Genomics rose more than 9% in premarket trading Monday.It’s been quite the year for the life sciences company,Bionano Genomics(NASDAQ:BNGO). BNGO stock was trading for as little as 50 cents late last year before the short squeeze lifted the stock past it past the penny stock territory and then some.Source: Connect world / Shutterstock.comReddit traders believe that itsnovel gene diagnostic technology called Saphyrhas an incredible growth runway ahead. However, with its float at roughly 10%, the question is whether BNGO stock can establish its presence in the life sciences sector.Bionano Genomics game changer is Saphyr. The product is unique as it relies on gene sequencing and can map an entire genome to enable more effective detection of specific disorders. Moreover, it also allows for more effective integrated testing and accepts various samples, including tissue biopsies, cultured cells, and others.With over 2,500 cytogenetic labs, the company believes it has a massive addressable market of over $3 billion. However, several risks can currently outweigh the upside of investing in BNGO stock at this time.The Bull CaseNaturally, the bull case for BNGO stock is linked to the success of the Saphyr device. Bionano received a huge boost last year. It posted the results of a study that highlighted how Saphyr outperformed a device developed by its rivalPacific Biosciences(NASDAQ:PACB). The genomics sector willramp up to $62.9 billionby 2028, growing at a compound annual growth rate of 15.3% from 2021 to 2028.The company is finally showing signs of promise. Its first-quarter results sawits revenues rise by 179%on a year-over-year basis to $3.2 million, which comfortably surpassed estimates of $2.9 million. It alsoposted a net loss of $9.9 million, which showed a solid improvement over the $10.5 million net loss is generated in the same period last year.Bionano analyzed more samples in the first quarter than ever before and shipped 11 Saphyr systems in the period. It hopes to take itsinstalled base up to 150 systemsby the conclusion of 2021. In that case, BNGO stock could keep its momentum if it makes significant strides towards its goals.The Bear CaseThere are several risks that Bionano currently faces, which are chomping away at its upside. The first is the stiff competition in the sector. In an industry where there is so much potential for growth, competition is imperative. Bionano has done well to convince investors that it’s carved a niche in one of the subsectors of the market. However, with several crossovers in the sectors, that notion is mostly inaccurate.Moreover, with the high competition, companies must focus on product security and differentiation. For example, though Bionano has registered several patents concerning Saphyr, it has outsourced some key manufacturing components. This raises questions about whether competitors can produce similar types of products down the road.Furthermore,  it must continue to have enough cash to meet its expenditures on research and development. However, Bionano’s cash flows from operating activities were negative last year and were offset by common stock sales and exercise of stock warrants. Hence, the company needs to look at ways to maintain its cash balance that doesn’t involve shareholder dilution.Concluding Thoughts On BNGO StockSix-month returns for Bionano stock are at a dumbfounding 1,150% due to the Reddit-induced short squeeze. However, the stock is now back to earth, and we can finally get down to the brass tacks.Its Saphyr system has a robust growth runway ahead, but the risks surrounding its bull case are sizeable at this time. Therefore, it’s tough to invest in the stock unless it makes meaningful progress in the expansion of Saphyr.On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":105,"commentSize":31,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}